Glioma– tag –
-
Oncology Drug
Glioblastoma Series | Part 9 (Finale): Fewer Moves, Deeper Reach — Answering Plasticity, Diversity, and State Shifts
Fewer Moves, Deeper Reach — Answering Plasticity, Diversity, and State Shifts This closing chapter weaves the series into design principles that tackle GBM’s plasticity (OPC/AC/MES transitions), intratumoral diversity, and therapy-driven... -
Oncology Drug
Glioblastoma Series | Part 8: Who Excels Where? — Country Strengths, Access Gaps, and Implementation Paths
Who Excels Where? — Country Strengths, Access Gaps, and Implementation Paths The same plan can reach very different depths depending on the country and center. This chapter maps global strengths across basic research, clinical neuro-onco... -
Oncology Drug
Glioblastoma Series | Part 7: Global Landscape — A Modality-by-Modality Development Map
Global Landscape — A Modality-by-Modality Development Map Building on seed (pre-CC), niche (microenvironment), mobility, plasticity, and composite diagnostics, this chapter surveys GBM development by therapeutic modality. We focus on des... -
Oncology Drug
Glioblastoma Series | Part 6: Seeing What Matters — Composite Diagnostics (Imaging × Transcriptome × CNV)
Seeing What Matters — Composite Diagnostics (Imaging × Transcriptome × CNV) Therapy moves only when we can answer “for whom, when, and what.” This chapter maps a beginner-friendly framework for composite diagnostics across imaging, trans... -
Oncology Drug
Glioblastoma Series | Part 5: Plasticity & Escape — A Gentle Guide to OPC/AC/MES State Transitions
Plasticity & Escape — A Gentle Guide to OPC/AC/MES State Transitions Why do single agents rarely suffice? Because GBM has plasticity—it can shift among OPC-like, AC-like, and MES-like faces. Let’s build intuition and turn it into a p... -
Oncology Drug
Glioblastoma Series | Part 4: The Moving Tumor — Intuitive Guide to ECM, Adhesion, and White-Matter Tract Invasion
The Moving Tumor — Intuitive Guide to ECM, Adhesion, and White-Matter Tract Invasion Why does GBM come back even after “maximal” surgery? This beginner-first chapter explains the mobility of GBM via ECM, adhesion signaling, and the highw... -
Oncology Drug
Glioblastoma Series | Part 3: Extinguishing the Spark — Microenvironment & Immunity (MIF–CD74 Primer)
Extinguishing the Spark — Microenvironment & Immunity (MIF–CD74 Primer) This beginner-friendly chapter looks beyond the tumor mass to the “place” that makes GBM easier to grow: the microenvironment. We introduce brain immunity, ECM, ... -
Oncology Drug
Glioblastoma Series | Part 2: Where It Begins — SVZ Hypothesis and Precancerous Cells
Where It Begins — SVZ Hypothesis and Precancerous Cells (pre-CC) Beyond the tumor mass: a beginner’s map of how GBM may arise, diversify, and interact with its “niche”. Today’s Goals (3-Minute Preview) Understand what the SVZ (subventric... -
Oncology Drug
Glioblastoma Series | Part 1: Clinical Map — Symptoms, Diagnosis, Standard of Care, and the Role of TTF
A gentle, beginner-friendly walkthrough of GBM care from first symptoms to initial therapy and what to consider at recurrence—using clear, minimal jargon. Today’s Goals (3-Minute Preview) Recognize common presenting symptoms that trigger... -
Oncology Drug
Glioblastoma Series | Part 0: Primer — Brain Basics & a By-the-Numbers View of GBM
A beginner-friendly introduction: understand the brain’s building blocks and a simple, number-based overview of GBM (incidence, prognosis, and quality of life). Series Table of Contents Part 0 | GBM Primer: Brain Basics and By-the-Number...
1